Trial Profile

Neoadjuvant Chemotherapy Combined with PD-1 blockade in resectable locally advanced Head and Neck Squamous Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Cisplatin; Docetaxel; Paclitaxel
Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

28 Jun 2024 Results for the 2 year disease-free survival (DFS), overall survival (OS) and quality of life (QOL) for neoadjuvant camrelizumab combined with chemotherapy in locally advanced Head and Neck Squamous cell carcinoma (HNSCC), published in the Oral Oncology
08 Jul 2022 New trial record
29 Jun 2022 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com